ANGELS–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chief Executive Officer, President and Founder of Puma, will provide an overview of the company at 11:00 a.m. PST/2:00 p.m. 00 EST Jan 19 at B. Riley Securities Virtual 3rd Annual Oncology Conference. A live webcast of Mr. Auerbach’s presentation will be accessible via registration on the event website at https://brileyoncology22.sequireevents.com/. A replay of the presentation will be available at the same address.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products to improve cancer care. Puma has licensed worldwide development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral, was approved by the U.S. Food and Drug Administration in 2017 for extended adjuvant treatment of adult patients with HER2 overexpressed/enhanced early stage breast cancer following adjuvant therapy based on trastuzumab, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received at least two anti-HER2-positive regimens. HER2 in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with hormone receptor-positive, HER2-overexpressed/amplified early-stage breast cancer who are at less than one year from the end of prior adjuvant treatment with trastuzumab. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.

Further information about Puma Biotechnology is available at https://www.pumabiotechnology.com.

Source link

Leave A Reply